San Jose, United States
Rani Therapeutics is a clinical-stage biotech company founded in 2012, headquartered in the United States, with the slogan "Making Oral Biologics a Reality." The company has developed a groundbreaking platform technology, the RaniPill™, which enables the oral delivery of biologic drugs. This is a significant advancement as it eliminates the need for traditional injections, offering a more patient-friendly alternative.
The RaniPill™ capsule has the capability to deliver an injection to the intestinal wall, where pain receptors are minimal, offering a less invasive method of drug delivery. It has achieved bioavailability levels similar to those of subcutaneous injections, showcasing its efficacy and potential to revolutionize drug delivery methods.
With millions of patients reliant on chronic self-injections, the oral versions of biologics developed by Rani Therapeutics present an opportunity to transform medicine and significantly improve patient outcomes. The company secured a substantial $45.00M Post-IPO Debt investment on 08 August 2022, indicating the confidence and support of investors in their innovative approach to drug delivery.
The growth and development of Rani Therapeutics showcase the potential to address a critical need in the biotechnology and pharmaceutical industries, positioning the company as a pioneer in advancing the accessibility and effectiveness of biologic drugs. As a result, the company's innovation and recent investment garner attention as they strive to make a meaningful impact on the healthcare sector.
